ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Highly Effective Short Course Therapy to Prevent Infection after Transplantation from HCV-Infected Organ Donors to Uninfected Recipients across Multiple Organ Types

A. Humar1, M. Cypel1, D. Kumar1, H. Dahari2, R. Vanin Pinto Ribeiro1, N. Marks1, N. Kamkar1, I. Bahinskaya1, F. Onofrio3, M. A. Zahoor3, O. Cerrochi3, K. Tinckam1, S. J. Kim1, T. W. Reichman1, M. McDonald1, T. K. Waddell1, G. Sapisochin1, M. Selzner1, S. Keshavjee1, H. L. Janssen3, B. E. Hansen3, L. Singer1, J. Feld3

1Transplant Centre, Toronto General Hospital, Toronto, ON, Canada, 2Loyala University, Chicago, IL, 3Toronto General Hospital, Toronto, ON, Canada

Meeting: 2020 American Transplant Congress

Abstract number: LB-3

Keywords: Donors, marginal, Hepatitis C, High-risk

Session Information

Session Name: Late Breaking Oral Abstract

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 3:39pm-3:51pm

Location: Virtual

*Purpose: An increasing percentage of potential organ donors are infected with hepatitis C virus (HCV). Establishment of HCV infection in uninfected recipients is near-universal with the requirement for post-transplant antiviral treatment. Prevention of HCV infection with a simplified regimen would be preferable.

*Methods: HCV-uninfected organ recipients were treated with ezetimibe 10 mg (an HCV entry inhibitor) and glecaprevir/pibrentasvir 300 mg/120 mg one dose before and once daily for 7 days after transplantation from HCV-infected donors. HCV RNA was assessed daily for 14 days and then weekly to 12 weeks post-transplant. The primary endpoint was prevention of HCV infection as evidenced by undetectable serum HCV RNA 12 weeks after transplant.

*Results: 30 patients received transplants (13 lung, 10 kidney, 6 heart and 1 kidney-pancreas) from 18 HCV-infected donors. The median donor viral load was 4.90 log10IU/mL (range 1.18-7.13 log10IU/mL) and included different HCV genotypes (9 genotype 1, 2 genotype 2, 5 genotype 3 and 2 genotype unknown). The treatment regimen was 100% effective in preventing HCV infection in the recipients and all 30 patients remain HCV RNA negative at last follow-up (median 27 weeks, range 5-45 weeks post-transplant). Low-level viremia was transiently detectable in 20 (67%) recipients in the early post-transplant period but never beyond day 11. Treatment was well tolerated, with transient ALT and CK elevations noted during treatment that resolved with treatment completion. Two recipients died of unrelated causes and neither were ever viremic for HCV.

*Conclusions: Ezetimibe combined with glecaprevir/pibrentasvir given one dose before and for 7 days after transplant was a completely effective and simplified regimen for preventing transmission of HCV infection in recipients of different organs from HCV-infected donors (registration NCT04017338).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Humar A, Cypel M, Kumar D, Dahari H, Ribeiro RVaninPinto, Marks N, Kamkar N, Bahinskaya I, Onofrio F, Zahoor MA, Cerrochi O, Tinckam K, Kim SJ, Reichman TW, McDonald M, Waddell TK, Sapisochin G, Selzner M, Keshavjee S, Janssen HL, Hansen BE, Singer L, Feld J. Highly Effective Short Course Therapy to Prevent Infection after Transplantation from HCV-Infected Organ Donors to Uninfected Recipients across Multiple Organ Types [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/highly-effective-short-course-therapy-to-prevent-infection-after-transplantation-from-hcv-infected-organ-donors-to-uninfected-recipients-across-multiple-organ-types/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences